Drugs / Arhalofenate
Arhalofenate
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 26 trials · 1 met primary | ||||||
| Phase 2 | NCT02252835 | Aug → Dec 2014 | gout | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT02063997 | Mar 2014 → Jan 2015 | gout | Gilead Sciences | Completed | Met primary |
| Phase 2 | NCT01416402 | Aug → Oct 2011 | gout | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01399008 | Jun 2011 → Feb 2012 | gout | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01336686 | May → Nov 2011 | gout | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00814372 | Dec 2008 → Feb 2010 | type 2 diabetes mellitus | Gilead Sciences | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00353587 | May 2006 → Nov 2007 | type 2 diabetes mellitus | Gilead Sciences | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Arhalofenate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01336686 ↗ |
| Known as | ARH | “Arhalofenate (ARH), in development for gout, has uricosuric and anti-flare activities.” PMID 27980008 ↗ Dec 2016 |
| Known as | JNJ-39659100 | “A Phase 2 Multicenter, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Study to Evaluate the Safety and Efficacy of MBX-102/JNJ-39659100 in Patients With...” NCT00814372 ↗ |
| Known as | MBX-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00353587 ↗ |
| Known as | Metaglidasen | “Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin” NCT00353587 ↗ |
| Route | Oral | “three dose levels of MBX-102 (200, 400, 600 mg) given orally” NCT00353587 ↗ |